论文部分内容阅读
肿瘤浸润腋窝下淋巴结的数目已作为决定乳腺癌病人是否作辅助治疗的原始参数。因为这类病人复发的危险性高,而且生存期短。20%～30%淋巴结阴性的患者也会发生复发或远处转移。对于预后不良的患者,乳腺癌研究的主要目标已经不再依靠淋巴结的转移情况,而是采用能预测预后的肿瘤相关标记来予以鉴别。一种研究途径已建立在对大多数上皮肿瘤的观察以及对那些能与具有向远端器官转移能力的浸润癌产生协同作用
The number of tumor-infiltrating axillary lymph nodes has been used as the original parameter to determine whether breast cancer patients should be treated as adjuvants. Because these patients have a high risk of recurrence and short survival. 20% to 30% of lymph node negative patients also have recurrence or distant metastasis. For patients with poor prognosis, the main goal of breast cancer research is no longer dependent on the lymph node metastasis, but is differentiated using tumor-associated markers that can predict prognosis. A research approach has been established in the observation of most epithelial tumors and synergy with invasive cancers that have the ability to metastasize to distant organs.